Yosuke Toya1, Shotaro Nakamura1, Kazumitsu Tomita2, Nozomi Matsuda3, Keinosuke Abe4, Yukito Abiko5, Shunsuke Orikasa6, Risaburo Akasaka7, Toshimi Chiba1, Noriyuki Uesugi8, Tamotsu Sugai8, Takayuki Matsumoto1. 1. Division of Gastroenterology, Department of Internal Medicine. 2. Department of Internal Medicine, Hanamakionsen Hospital affiliated with Iwate Medical University, Hanamaki, Japan. 3. Department of Gastroenterology, Yamamotokumiai Hospital, Noshiro, Japan. 4. Department of Gastroenterology, Iwate Prefectural Miyako Hospital, Miyako. 5. Department of Gastroenterology, Morioka Red Cross Hospital, Morioka, Japan. 6. Department of Gastroenterology, Iwate Prefectural Kuji Hospital, Kuji, Japan. 7. Department of Gastroenterology, Hachinohe Red Cross Hospital, Hachinohe, Japan. 8. Division of Molecular Diagnostic Pathology, Department of Pathology, School of Medicine, Iwate Medical University, Morioka.
Abstract
BACKGROUND AND AIM: There have been some descriptions of dabigatran-induced esophagitis in the literature. The aim of this study was to examine the prevalence and endoscopic characteristics of the disease. METHODS: We reviewed the endoscopic database and medical records of 91 patients with dabigatran internal use who underwent upper gastrointestinal endoscopy. The frequency of dabigatran-induced esophagitis and its endoscopic findings were retrospectively analyzed. In addition, the clinical characteristics were compared between patients with dabigatran-induced esophagitis and those without the disease. RESULTS: Dabigatran-induced esophagitis was found in 19 of 91 (20.9%) patients. Of the 19 patients with the esophagitis, 18 (94.7%) showed longitudinally sloughing epithelial casts in the mid and/or lower esophagus, which may be characteristic endoscopic findings of this disease. Symptomatic patients were more frequent in patients with dabigatran-induced esophagitis (68.4%) than those without (37.5%, P = 0.02). Other factors including age, gender, coexistence of hiatal hernia, gastroesophageal reflux disease, or concomitant other medications did not differ between the two groups. CONCLUSIONS: Dabigatran causes the esophageal mucosal injury in approximately 20% of patients. Longitudinally sloughing casts in the distal esophagus are characteristic of dabigatran-induced esophagitis.
BACKGROUND AND AIM: There have been some descriptions of dabigatran-induced esophagitis in the literature. The aim of this study was to examine the prevalence and endoscopic characteristics of the disease. METHODS: We reviewed the endoscopic database and medical records of 91 patients with dabigatran internal use who underwent upper gastrointestinal endoscopy. The frequency of dabigatran-induced esophagitis and its endoscopic findings were retrospectively analyzed. In addition, the clinical characteristics were compared between patients with dabigatran-induced esophagitis and those without the disease. RESULTS:Dabigatran-induced esophagitis was found in 19 of 91 (20.9%) patients. Of the 19 patients with the esophagitis, 18 (94.7%) showed longitudinally sloughing epithelial casts in the mid and/or lower esophagus, which may be characteristic endoscopic findings of this disease. Symptomatic patients were more frequent in patients with dabigatran-induced esophagitis (68.4%) than those without (37.5%, P = 0.02). Other factors including age, gender, coexistence of hiatal hernia, gastroesophageal reflux disease, or concomitant other medications did not differ between the two groups. CONCLUSIONS:Dabigatran causes the esophageal mucosal injury in approximately 20% of patients. Longitudinally sloughing casts in the distal esophagus are characteristic of dabigatran-induced esophagitis.
Authors: Sergio Castrejón-Castrejón; Marcel Martínez Cossiani; Marta Ortega Molina; Carlos Escobar; Consuelo Froilán Torres; Nerea Gonzalo Bada; Marta Díaz de la Torre; José Manuel Suárez Parga; José Luis López Sendón; José Luis Merino Journal: J Interv Card Electrophysiol Date: 2019-11-12 Impact factor: 1.900